GlassScriptPhysician profile
Ryan Matthew Lingle
NPI 1891290631
$3,074.11
in general payments reported to CMS, 2019-2025
31 companies · $665 in 2025
The $665 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.26 · 2021: $67.51 · 2022: $556 · 2023: $946 · 2024: $824 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $523.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $319.63 | 2022-2025 | |
| Pfizer INC. | $253.26 | 2022-2025 | |
| Lilly USA, LLC | $215.07 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.56 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $137.86 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Supernus Pharmaceuticals, INC. | $137.77 | 2024 | Qelbree |
| Amgen INC. | $133.93 | 2022-2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $125.05 | 2023-2025 | |
| Lundbeck LLC | $112.35 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $106.74 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $95.34 | 2022-2025 | Veozah, Myrbetriq |
| Mylan Specialty L.P. | $94.12 | 2023-2024 | Yupelri |
| Vanda Pharmaceuticals INC. | $71.47 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $64.83 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $61.20 | 2022 | |
| Sumitomo Pharma America, INC. | $44.22 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $42.64 | 2023-2024 | |
| Dexcom, INC. | $37.06 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $32.25 | 2023 | Cologuard Collection Kit |
| Nevro Corp. | $31.84 | 2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $31.46 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $28.15 | 2022-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.75 | 2023-2025 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Idorsia Pharmaceuticals US INC | $26.81 | 2023-2024 | Quviviq |
| Intuitive Surgical, INC. | $26.22 | 2025 | |
| Esperion Therapeutics, INC. | $25.51 | 2021 | |
| Eisai INC. | $24.80 | 2021 | |
| Radius Health, INC. | $19.17 | 2023 | Tymlos |
| Viatris Specialty LLC | $15.70 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lingle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.